Erectile Dysfunction Treatment Market, By Drugs (Sildenafil (Viagra), Vardenafil (Levitra Staxyn), Tadalafil (Cialis), Avanafil (Stendra), Udenafil (Zydena), Others), By Route of Administration (Oral drugs, Injections, Topical application), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Erectile Dysfunction (ED), also commonly referred to as impotence, is a medical condition characterized by the consistent or recurrent inability to achieve and maintain an erection sufficient for satisfactory sexual activity. Sildenafil (Viagra), Tadalafil (Cialis), Vardenafil (Levitra, Staxyn), Avanafil (Stendra), Udenafil (Zydena), and other medications work by enhancing the effects of nitric oxide, a natural chemical in the body that relaxes the muscles in the penis, allowing for increased blood flow and thus facilitating an erection.
Market Dynamics
The key players in operating in the market are focusing on inorganic growth strategies such as acquisitions and agreements for Erectile Dysfunction (ED), which is expected to propel the global erectile dysfunction treatment market growth over the forecast period. For instance, in May 2022, Aspargo Laboratories, Inc., a privately-held specialty pharmaceutical company, announced the acquisition of the prescription brand, BANDOL (sildenafil oral suspension) from Laboratorios Rubio S.A., a specialty pharmaceutical company headquartered in Barcelona, Spain. BANDOL is indicated for the treatment of Erectile Dysfunction (ED). Moreover, in March 2023, Dicot is a pharmaceutical company started developing a novel potency drug aimed to become the first choice for treatment of erectile dysfunction, and entered into a consultancy agreement with Dr.Harin Padma-Nathan, a world leading medical expert in male sexual dysfunctions. Dr. Padma-Nathan was involved in the development of the drugs for erectile dysfunction currently on the market, e.g., as Lead Principal Investigator during the development of Viagra and Cialis. His Viagra paper in The New England Journal of Medicine is the most cited paper in the field of urology.
Key features of the study:
This report provides an in-depth analysis of the global erectile dysfunction treatment market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year. It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global erectile dysfunction treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Mangoceuticals, Inc, Futura Medical, CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific, Cipla Ltd , Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic LLC
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global erectile dysfunction treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global erectile dysfunction treatment market